Kaufman, Howard L.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,992

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology

Polyomavirus and related diseasesNonmelanoma Skin Cancer Studies

Cited by 1,236

Integrating oncolytic viruses in combination cancer immunotherapy

Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology

Virus-based gene therapy researchImmunotherapy and Immune Responses

Cited by 704

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 642

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction

Zhang, W., Yu, Y., Hertwig, F., Thierry-Mieg, J., Zhang, W., Thierry-Mieg, D., Wang, J., Furlanello, C., Devanarayan, V., Cheng, J., et al. (2015) · Genome Biology

Gene expression and cancer classificationNeuroblastoma Research and Treatments

Cited by 393

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

Kaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., et al. (2018) · Journal for ImmunoTherapy of Cancer

Polyomavirus and related diseasesNonmelanoma Skin Cancer Studies

Cited by 334

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

Ugurel, S., Schrama, D., Keller, G., Schadendorf, D., Bröcker, E.-B., Houben, R., Zapatka, M., Fink, W., Kaufman, H. L., & Becker, J. C. (2008) · Cancer Immunology, Immunotherapy

Chemokine receptors and signalingCutaneous Melanoma Detection and Management

Cited by 88

Molecular Targeting in Oncology

Kaufman, H. L., Wadler, S., & Antman, K. H. (2008) · Cancer Drug Discovery and Development

Cancer Mechanisms and TherapyLung Cancer Treatments and Mutations

Cited by 20

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

Chesney, J., Collichio, F., Andtbacka, R. H. I., Puzanov, I., Glaspy, J., Milhem, M., Hamid, O., Cranmer, L., Saenger, Y., Ross, M., et al. (2016) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 15